Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on February 7, 2013. The filing discloses the adoption of the 2013 Executive Incentive Plan by the Compensation Committee of the Board of Directors. The plan covers the period from January 1, 2013, to December 31, 2013, and applies to named executive officers (NEOs) and the principal financial officer.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation targets.
| Participant | Role | Incentive Target |
|---|---|---|
| Brian M. Culley | Chief Executive Officer | $196,875 |
| Patrick L. Keran | President and Chief Operating Officer | $196,875 |
| Gregory D. Gorgas | Senior Vice President, Commercial | 30% of base salary |
| Brandi L. Roberts | Chief Financial Officer and Senior Vice President | 30% of base salary |
| Chief Medical Officer | Chief Medical Officer | 35% of base salary |
| Senior Vice President, Development | Senior Vice President, Development | 30% of base salary |
Material Changes
The primary material change is the formal adoption of the 2013 Executive Incentive Plan. This establishes specific performance-based compensation targets for senior leadership for the 2013 fiscal year. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
Performance Objectives: Corporate objectives for the incentive plan include progress on the research and development of the lead product candidate ANX-188 (nonclinical, clinical, and regulatory activities), submission of scientific articles for publication, and maintaining specified levels of capital.
Payment Terms: Awards are generally paid in cash in a single sum on or before March 14, 2014. Payment is contingent upon continued employment until the payment date.
Discretion and Risks: The Compensation Committee retains absolute discretion to abolish the plan, alter terms, or determine award amounts (including paying less than the target or nothing at all) based on performance evaluation. If a participant's employment is terminated prior to payment, the Committee has absolute discretion regarding whether any award is paid.
Investor Verification Checklist
- Verify the company name is ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
- Confirm the specific corporate performance metrics for ANX-188 development that will determine the payout of the $196,875 targets for the CEO and COO.
- Review the full text of the 2013 Executive Incentive Plan (Exhibit 10.1) for detailed definitions of "specified levels of capital" and other performance criteria.
- Monitor the company's capital position to ensure it meets the liquidity objectives tied to executive compensation.